Our Approach
Building the Future of Oncology Treatment
Our investigational therapies evorpacept and ALX2004 are highly differentiated, potential first-in-class treatments designed to leverage promising targets in difficult-to-treat cancers.
Immunotherapy offers the potential to bring the powerful disease-fighting capabilities of the body’s natural defenses to bear against cancer.
Despite their promise, the full potential of immunotherapies has not yet been realized: Further innovation is essential to ensure that more patients can benefit meaningfully from them.
We founded ALX Oncology to fill this gap, and started by creating evorpacept, a molecule designed to inhibit CD47 while minimizing the dose-limiting toxicities inherent with previous CD47-blocking approaches.
In clinical studies across a wide range of tumor types, this novel approach has demonstrated significant potential to engage the innate immune system to improve patient outcomes and elevate the standard of care.
Leading the Field
Extensive preclinical and clinical research validates the innovative thinking and science behind evorpacept.
Our lead immuno-oncology compound, evorpacept, is designed to be a highly differentiated CD47-blocking agent and has demonstrated a well-tolerated safety profile across multiple Phase 1 and Phase 2 clinical trials that have included more than 750 patients (data on file). Evorpacept showed improvement in overall response rates in the randomized Phase 2 ASPEN-06 clinical trial when evorpacept was added to trastuzumab, ramucirumab and paclitaxel in HER2+ advanced gastric cancer patients. Evorpacept is currently being evaluated across multiple tumor types in combination with many of the important cancer therapies available today. Evorpacept has the potential to transform clinical practice by becoming a critical component in standards of care across tumor types.
Learn More About Evorpacept
Compelling Potential
Evorpacept has been investigated in more than 750 patients to date.
Results from these clinical trials suggest that evorpacept’s proprietary design, combined with the wide range of cancers that overexpress CD47, can create the potential for new standards of care for many patients with solid tumor and hematologic cancers.
Explore Our Robust Data
Optimizing the EGFR-Targeting Potential of ADCs
The epidermal growth factor receptor (EGFR) remains one of the most validated and clinically actionable targets in oncology.
Antibody-drug conjugates (ADCs) offer the potential to expand beyond the current limitations of EGFR-directed therapies, through targeted delivery of cytotoxic payloads to EGFR-expressing cancer cells. While multiple previous attempts to develop safe, effective EGFR-targeted ADCs have failed, ALX Oncology is driving a new, highly differentiated ADC approach to target EGFR-expressing tumors.
Using our proprietary linker-payload platform created at our labs in California, ALX Oncology protein engineers designed and developed ALX2004 to optimize efficacy while minimizing off-target toxicity.
Learn More About ALX2004